welcome to oneGRAVESvoice- a positively charged Graves' disease and thyroid eye disease community.
- join today!
- log in
The New England Journal of Medicine Publishes Comprehensive Data From Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (Teprotumumab-Trbw) for Thyroid Eye Disease
Horizon Therapeutics plc announced that The New England Journal of Medicine has published comprehensive results of the Phase 3 OPTIC clinical trial evaluating TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease (TED). OPTIC is part of the largest clinical program in TED and demonstrates that TEPEZZA provides significant improvements in proptosis (eye bulging) and diplopia (double vision) compared to placebo.
TEPEZZA is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) that is administered to patients once every three weeks for a total of eight infusions. TEPEZZA was approved by the U.S. Food and Drug Administration (FDA) on January 21, 2020 – making it the first and only medicine approved for the treatment of TED. The medicine received Priority Review, Orphan Drug, Fast Track and Breakthrough Therapy designations from the FDA.
More from Teprotumumab News:
More from Teprotumumab Research:
(Author: Raymond S. Douglas)
Orbital Pain – Dr. Raymond Douglashttps://www.youtube.com/watch?v=qHqEGxMr...
ENFOQUE en la salud ocularhttps://www.onegravesvoice.com/wp-conten...
Pathogenesis of Thyroid Eye Disease: Review and Update on Molecular MechanismsOrbital changes in thyroid orbitopathy (...
The Medical University of South Carolina Health Graves’ Eye Disease ClinicThe Medical University of South Carolina...
Death by Suicide in Graves’ Disease and Graves’ Orbitopathy: A Nationwide Danish Register StudyBackground: Graves' disease (GD) is ass...
Thyroid Eye Disease Charitable TrustThyroid Eye Disease Charitable Trust (TE...
Kellogg Eye Center – Thyroid Eye Disease CenterAt the Thyroid Eye Disease Clinic at the...